Revelation Biosciences, Inc. - Common Stock (REVB)
0.7600
-0.0100 (-1.30%)
NASDAQ · Last Trade: Jul 3rd, 2:50 PM EDT
Detailed Quote
Previous Close
0.7700
Open
0.7700
Bid
0.7599
Ask
0.7600
Day's Range
0.7600 - 0.8000
52 Week Range
0.7020 - 56.00
Volume
364,361
Market Cap
4.79M
PE Ratio (TTM)
-0.0086
EPS (TTM)
-88.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,711,617
Chart
About Revelation Biosciences, Inc. - Common Stock (REVB)
Revelation Biosciences Inc is a biotechnology company focused on developing innovative therapies and diagnostics to address unmet medical needs, particularly in the areas of respiratory and immune-related diseases. The company leverages its proprietary platforms to explore novel treatments that may enhance immune response or provide protection against infectious agents, utilizing advanced research methodologies and clinical trials to validate its programs. By combining cutting-edge science with a commitment to improving patient care, Revelation Biosciences aims to deliver transformative solutions in the rapidly evolving healthcare landscape. Read More
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “REVB.” The CUSIP number for the common stock following the reverse stock split will be 76135L705.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial exercise date.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial exercise date. The closing of the offering is expected to occur on or about May 29, 2025, subject to the satisfaction of customary closing conditions.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company’s Board of Directors.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced a new target indication for Gemini for the prevention of infection in severe burn patients requiring hospitalization (the GEM-PBI program). The use of Gemini for the prevention of infection in severe burn patients, as well as the prevention of infection post-surgery (the GEM-PSI program) are a part of the patent family Revelation previously licensed from Vanderbilt University.
